Transformative developments have impacted the field of prostate cancer and helped reshape the approach to treating and managing patients with this disease. With new therapeutic strategies...
Chirag A. Shah, MD: When we talk about the mechanism of action of PARP inhibitors, it is a molecule that’s primarily involved in DNA repair. In...
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in early-risk, high-risk, HER2-negative breast cancer and germline patients. BRCA Mutations, according to...
Recent Comments